FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.

Autor: Stein L; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA., Murugesan K; Foundation Medicine Inc, Cambridge, MA, USA., Reeser JW; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Risch Z; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Wing MR; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Paruchuri A; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Samorodnitsky E; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Hoskins EL; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA., Dao T; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Smith A; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Le D; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Babcook MA; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Chang YS; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Avenarius MR; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Department of Pathology, The Ohio State University, Columbus, OH, USA., Imam M; Florida Cancer Specialists, Orlando, FL, USA., Freud AG; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Department of Pathology, The Ohio State University, Columbus, OH, USA., Roychowdhury S; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA. Sameek.Roychowdhury@osumc.edu.; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. Sameek.Roychowdhury@osumc.edu.
Jazyk: angličtina
Zdroj: NPJ precision oncology [NPJ Precis Oncol] 2024 Sep 17; Vol. 8 (1), pp. 207. Date of Electronic Publication: 2024 Sep 17.
DOI: 10.1038/s41698-024-00683-x
Abstrakt: Genomic alterations in fibroblast growth factor receptor (FGFR) genes are present in a small number of metastatic pancreatic ductal adenocarcinomas (PDAC) and may represent an emerging subgroup of patients likely to benefit from FGFR targeted therapies. Here we present four FGFR2 fusion-positive metastatic PDAC patients who exhibited durable responses or disease control to FGFR kinase inhibitors. Utilizing our custom FGFR focused cell-free DNA assay, FGFR-Dx, we serially monitored variant allele fractions of FGFR2 fusions during FGFR inhibitor treatment and observed dynamic changes correlating with clinical responses. Genomic analysis of 30,229 comprehensively profiled pancreatic cancers revealed FGFR1-3 fusions in 245 cases, an incidence of 0.81%. FGFR fusions were generally mutually exclusive from other known oncogenes. Our findings provide clinical evidence for identifying and treating FGFR2 fusion-positive PDAC patients with FGFR targeted therapy.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: